Name: Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Enzyme Replacement Therapy (ERT), Gene Therapy, Substrate Reduction Therapy (SRT), Supportive / Symptomatic Treatment), By End-User (Hospitals, Specialty Clinics, Homecare Settings), By Therapy Modality (Biologics, Gene Therapy Platforms, Small Molecule Therapies), Forecast Period (2026-2035)
Brand: Orion Market Research
SKU: OMR2029584
Price: 2400 USD
Availability: InStock

Hunter Syndrome Treatment Market

SHARE ON:

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Enzyme Replacement Therapy (ERT), Gene Therapy, Substrate Reduction Therapy (SRT), Supportive / Symptomatic Treatment), By End-User (Hospitals, Specialty Clinics, Homecare Settings), By Therapy Modality (Biologics, Gene Therapy Platforms, Small Molecule Therapies), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2029584 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Hunter syndrome treatment market size was valued at $1.07 billion in 2025 and is projected to reach $2.15 billion by 2035, growing at a CAGR of 7.23% between 2026 and 2035. The market focuses on therapies addressing mucopolysaccharidosis type II (MPS II), a rare genetic lysosomal storage disorder requiring long-term treatment solutions. A key driver supporting market growth is the increasing global burden of rare diseases. According to the World Health Organization, rare diseases affect approximately 400 million people worldwide, highlighting the urgent need for targeted therapies. Additionally, regulatory support for orphan drugs and increasing R&D investments are accelerating innovation in gene therapy and biologics. The expansion of healthcare infrastructure and specialized treatment centers is further improving access to advanced therapies. End-use industries such as hospitals, specialty clinics, and homecare settings are playing a critical role in delivering long-term treatment and improving patient outcomes.

Market Dynamics

Rising Rare Disease Prevalence Driving Market Growth

The increasing prevalence of rare genetic disorders is a major factor driving the Hunter syndrome treatment market. According to the U.S. Food and Drug Administration, more than 7,000 rare diseases have been identified, with a growing number requiring specialized treatment approaches. Additionally, the Pharmaceutical Research and Manufacturers of America reports that over 50% of new drug approvals in recent years are focused on rare diseases. Increasing investments in gene therapy and biologics between 2023 and 2026 are accelerating the development of advanced treatments. Companies are focusing on innovative platforms such as enzyme replacement therapies and gene delivery systems to enhance treatment efficiency and long-term outcomes. Strategic collaborations, clinical trials, and regulatory approvals are further strengthening the growth of the market.

High Treatment Costs Limiting Market Growth

Despite strong growth potential, the market faces challenges related to high treatment costs and limited accessibility. Hunter syndrome therapies, particularly enzyme replacement and gene therapies, are expensive due to complex manufacturing processes and specialized clinical requirements. According to the Organisation for Economic Co-operation and Development, healthcare costs continue to rise globally, placing pressure on healthcare systems and patient affordability. Limited patient populations and high R&D costs further increase pricing challenges. Additionally, regulatory complexities and long clinical trial timelines create barriers to market entry. To address these challenges, companies are focusing on cost optimization, expanding manufacturing capabilities, and developing alternative treatment approaches to improve accessibility.

Market Segmentation

Based on the Treatment Type, the market is segmented into Enzyme Replacement Therapy (ERT), Gene Therapy, Substrate Reduction Therapy (SRT), and Supportive / Symptomatic Treatment.
Based on the end-user, the market is segmented into hospitals, specialty clinics, and homecare settings.
Based on the therapy modality, the market is segmented into biologics, gene therapy platforms, and small molecule therapies.

Enzyme Replacement Therapy Segment Leads the Market

The enzyme replacement therapy segment holds a dominant position in the Hunter syndrome treatment market due to its established clinical effectiveness and widespread adoption. These therapies are commonly used in hospitals and specialty clinics for long-term disease management. Increasing demand for proven treatment options and regulatory approvals between 2022 and 2026 are driving segment growth. Companies are focusing on improving enzyme delivery efficiency and expanding access to treatment across emerging markets.

Gene Therapy Segment to Record Strong Growth

The gene therapy segment is expected to witness strong growth due to advancements in genetic engineering and targeted treatment technologies. Gene therapy offers the potential for long-term or curative outcomes compared to conventional therapies. Increasing investments in biotechnology and clinical research are supporting the growth of this segment. Companies are developing innovative delivery platforms and expanding clinical trials to improve treatment effectiveness and patient outcomes.

Regional Outlook

The global hunter syndrome treatment market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the Hunter syndrome treatment market due to strong healthcare infrastructure and advanced biotechnology research capabilities. According to the U.S. Food and Drug Administration, the country leads in orphan drug approvals and rare disease research initiatives. Increasing investments in gene therapy and biologics, along with strong regulatory support, are driving market growth. The presence of leading pharmaceutical companies and advanced clinical trial infrastructure further strengthens the market.

China to Record Strong Growth

China is expected to witness strong growth due to increasing healthcare investments and expansion of biotechnology research. According to the International Trade Centre, China continues to expand its pharmaceutical manufacturing capabilities and global trade presence. Government initiatives supporting rare disease treatment and increasing healthcare access are further driving market growth in the region.

Competitive Landscape

The Hunter syndrome treatment market is highly competitive, characterized by strong focus on innovation and strategic collaborations. Leading companies such as Takeda Pharmaceutical Company Limited, GC Biopharma Corp., JCR Pharmaceuticals Co., Ltd., Denali Therapeutics Inc., and RegenxBio Inc. are focusing on expanding product portfolios, advancing gene therapy platforms, and strengthening global presence to maintain competitive advantage.

Recent Developments

In April 2026, Denali Therapeutics Inc. regained full rights to its investigational therapy DNL593 (PTV:PGRN) after Takeda Pharmaceutical Company Limited terminated their collaboration agreement. The company plans to continue independent clinical development using its TransportVehicle platform, strengthening its pipeline in neurodegenerative diseases and expanding control over its proprietary technology.
In February 2026, Denali Therapeutics Inc. presented clinical progress of its Enzyme TransportVehicle platform at the 2026 WORLDSymposium, highlighting advancements in Hunter syndrome (MPS II) treatment. The company reported positive Phase 1/2 data for tividenofusp alfa (DNL310), demonstrating sustained biomarker reduction and supporting its regulatory submission, strengthening its position in advanced enzyme replacement therapies.

The Report Covers

Market value data analysis of 2025 and forecast to 2035.
Annualised market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global hunter syndrome treatment market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying ‘who-stands-where’ in the market.

Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Hunter Syndrome Treatment Market Sales Analysis – Treatment Type | End-User | Therapy Modality ($ Million)
Hunter Syndrome Treatment Market Sales Performance of Top Countries

1.1 Research Methodology

Primary Research Approach
Secondary Research Approach

1.2 Market Snapshot

Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Hunter Syndrome Treatment Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Hunter Syndrome Treatment Market

2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes

Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Hunter Syndrome Treatment Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Hunter Syndrome Treatment Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Hunter Syndrome Treatment Market: Impact Analysis

Competitive Landscape

4.1 Competitive Dashboard – Hunter Syndrome Treatment Market Revenue and Share by Manufacturers

Hunter Syndrome Treatment Market Product Comparison Analysis
Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Takeda Pharmaceutical Company Limited

4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy

4.2.2 GC Biopharma Corp.

4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy

4.2.3 JCR Pharmaceuticals Co., Ltd.

4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy

4.2.4 Denali Therapeutics Inc.

4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy

4.2.5 RegenxBio Inc.

4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration

Global Hunter Syndrome Treatment Market Sales Analysis by Treatment Type ($ Million)

5.1 Enzyme Replacement Therapy (ERT)
5.2 Gene Therapy
5.3 Substrate Reduction Therapy (SRT)
5.4 Supportive / Symptomatic Treatment

Global Hunter Syndrome Treatment Market Sales Analysis by End-User ($ Million)

6.1 Hospitals
6.2 Speciality Clinics
6.3 Homecare Settings

Global Hunter Syndrome Treatment Market Sales Analysis by Therapy Modality ($ Million)

7.1 Biologics
7.2 Gene Therapy Platforms
7.3 Small Molecule Therapies

Regional Analysis

8.1 North American Hunter Syndrome Treatment Market Sales Analysis – Treatment Type | End-User | Therapy Modality ($ Million)

8.1.1 United States

8.1.2 Canada

8.2 European Hunter Syndrome Treatment Market Sales Analysis – Treatment Type | End-User | Therapy Modality ($ Million)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3 Asia-Pacific Hunter Syndrome Treatment Market Sales Analysis – Treatment Type | End-User | Therapy Modality ($ Million)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Hunter Syndrome Treatment Market Sales Analysis – Treatment Type | End-User | Therapy Modality ($ Million)

8.4.1 Latin America

8.4.2 Middle East and Africa

Company Profiles

9.1 Takeda Pharmaceutical Company Limited
9.1.1 Quick Facts
9.1.2 Company Overview
9.1.3 Product Portfolio
9.1.4 Business Strategies

9.2 GC Biopharma Corp.
9.2.1 Quick Facts
9.2.2 Company Overview

9.2.3 Product Portfolio
9.2.4 Business Strategies

9.3 JCR Pharmaceuticals Co., Ltd.
9.3.1 Quick Facts
9.3.2 Company Overview
9.3.3 Product Portfolio
9.3.4 Business Strategies

9.4 Denali Therapeutics Inc.
9.4.1 Quick Facts
9.4.2 Company Overview
9.4.3 Product Portfolio
9.4.4 Business Strategies

9.5 RegenxBio Inc.
9.5.1 Quick Facts
9.5.2 Company Overview
9.5.3 Product Portfolio
9.5.4 Business Strategies

9.6 Ultragenyx Pharmaceutical Inc.
9.6.1 Quick Facts
9.6.2 Company Overview
9.6.3 Product Portfolio
9.6.4 Business Strategies

9.7 Sobi
9.7.1 Quick Facts
9.7.2 Company Overview
9.7.3 Product Portfolio
9.7.4 Business Strategies

9.8 Sangamo Therapeutics, Inc.
9.8.1 Quick Facts
9.8.2 Company Overview
9.8.3 Product Portfolio
9.8.4 Business Strategies

9.9 Inventiva Pharma
9.9.1 Quick Facts
9.9.2 Company Overview
9.9.3 Product Portfolio
9.9.4 Business Strategies

9.10 Moderna, Inc.
9.10.1 Quick Facts
9.10.2 Company Overview
9.10.3 Product Portfolio
9.10.4 Business Strategies

9.11 Passage Bio, Inc.
9.11.1 Quick Facts
9.11.2 Company Overview

9.11.3 Product Portfolio
9.11.4 Business Strategies

9.12 Esteve Pharmaceuticals
9.12.1 Quick Facts
9.12.2 Company Overview
9.12.3 Product Portfolio
9.12.4 Business Strategies

9.13 Orchard Therapeutics
9.13.1 Quick Facts
9.13.2 Company Overview
9.13.3 Product Portfolio
9.13.4 Business Strategies

9.14 Abeona Therapeutics Inc.
9.14.1 Quick Facts
9.14.2 Company Overview
9.14.3 Product Portfolio
9.14.4 Business Strategies

9.15 Taysha Gene Therapies
9.15.1 Quick Facts
9.15.2 Company Overview
9.15.3 Product Portfolio
9.15.4 Business Strategies

9.16 Evox Therapeutics
9.16.1 Quick Facts
9.16.2 Company Overview
9.16.3 Product Portfolio
9.16.4 Business Strategies

9.17 Bloom Science
9.17.1 Quick Facts
9.17.2 Company Overview
9.17.3 Product Portfolio
9.17.4 Business Strategies

9.18 Codexis, Inc.
9.18.1 Quick Facts
9.18.2 Company Overview

9.18.3 Product Portfolio
9.18.4 Business Strategies

9.19 4D Molecular Therapeutics
9.19.1 Quick Facts
9.19.2 Company Overview
9.19.3 Product Portfolio
9.19.4 Business Strategies

9.20 BioMarin Pharmaceutical Inc.
9.20.1 Quick Facts
9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Hunter Syndrome Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

2. Global Enzyme Replacement Hunter Syndrome Therapy Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Gene Hunter Syndrome Therapy Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Substrate Reduction Hunter Syndrome Therapy Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

5. Global Supportive / Symptomatic Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Hunter Syndrome Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)

7. Global Hunter Syndrome Treatment for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Hunter Syndrome Treatment for Speciality Clinics Market Research and Analysis by Region, 2025–2035 ($ Million)

9. Global Hunter Syndrome Treatment for Homecare Settings Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Hunter Syndrome Treatment Market Research and Analysis by Therapy Modality, 2025–2035 ($ Million)

11. Global Biologics Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Gene Therapy Platforms Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

13. Global Small Molecule Therapies Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

14. Global Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

15. North America Hunter Syndrome Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

16. North America Hunter Syndrome Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

17. North America Hunter Syndrome Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)

18. North America Hunter Syndrome Treatment Market Research and Analysis by Therapy Modality, 2025–2035 ($ Million)

19. Europe Hunter Syndrome Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

20. Europe Hunter Syndrome Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

21. Europe Hunter Syndrome Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)

22. Europe Hunter Syndrome Treatment Market Research and Analysis by Therapy Modality, 2025–2035 ($ Million)

23. Asia-Pacific Hunter Syndrome Treatment Market Research and Analysis by Country, 2025–2035 ($ Million)

24. Asia-Pacific Hunter Syndrome Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

25. Asia-Pacific Hunter Syndrome Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)

26. Asia-Pacific Hunter Syndrome Treatment Market Research and Analysis by Therapy Modality, 2025–2035 ($ Million)

27. Rest of the World Hunter Syndrome Treatment Market Research and Analysis by Region, 2025–2035 ($ Million)

28. Rest of the World Hunter Syndrome Treatment Market Research and Analysis by Treatment Type, 2025–2035 ($ Million)

29. Rest of the World Hunter Syndrome Treatment Market Research and Analysis by End-User, 2025–2035 ($ Million)

30. Rest of the World Hunter Syndrome Treatment Market Research and Analysis by Therapy Modality, 2025–2035 ($ Million)

1. Global Hunter Syndrome Treatment Market Share by Treatment Type, 2025 Vs 2035 (%)

2. Global Enzyme Replacement Hunter Syndrome Therapy Treatment Market Share by Region, 2025 Vs 2035 (%)

3. Global Gene Hunter Syndrome Therapy Treatment Market Share by Region, 2025 Vs 2035 (%)

4. Global Substrate Reduction Hunter Syndrome Therapy Treatment Market Share by Region, 2025 Vs 2035 (%)

5. Global Supportive / Symptomatic Hunter Syndrome Treatment Market Share by Region, 2025 Vs 2035 (%)

6. Global Hunter Syndrome Treatment Market Share by End-User, 2025 Vs 2035 (%)

7. Global Hunter Syndrome Treatment for Hospitals Market Share by Region, 2025 Vs 2035 (%)

8. Global Hunter Syndrome Treatment for Speciality Clinics Market Share by Region, 2025 Vs 2035 (%)

9. Global Hunter Syndrome Treatment for Homecare Settings Market Share by Region, 2025 Vs 2035 (%)

10. Global Hunter Syndrome Treatment Market Share by Therapy Modality, 2025 Vs 2035 (%)

11. Global Biologics Hunter Syndrome Treatment Market Share by Region, 2025 Vs 2035 (%)

12. Global Gene Therapy Platforms Hunter Syndrome Treatment Market Share by Region, 2025 Vs 2035 (%)

13. Global Small Molecule Therapies Hunter Syndrome Treatment Market Share by Region, 2025 Vs 2035 (%)

14. Global Hunter Syndrome Treatment Market Share by Region, 2025 Vs 2035 (%)

15. US Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

16. Canada Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

17. UK Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

18. France Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

19. Germany Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

20. Italy Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

21. Spain Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

22. Russia Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

23. India Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

24. China Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

25. Japan Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

26. South Korea Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

27. Australia & New Zealand Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

28. ASEAN Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

29. Rest of Asia-Pacific Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

30. Latin America Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

31. Middle East & Africa Hunter Syndrome Treatment Market Size, 2025–2035 ($ Million)

Printable version
No restriction to number of users within the company

CONTACT SALES

Why buy from us?

Covers more than 15 major industries, which are further segmented into 90+ sectors
65% of our clients are loyal customers
120+ countries are covered in analysis
currently servicing 1000+ customers globally
100+ paid data sources mined to research
Our expert team will assist you with all research need and customization
Our expert research analyst will resolve your every query before and after purchasing the report

FAQS

The size of the Hunter Syndrome Treatment Market in 2025 is estimated to be around $1.07 billion.

United States holds the largest share in the Hunter Syndrome Treatment Market.

Leading players in the Hunter Syndrome Treatment Market Includes Takeda Pharmaceutical Company Limited, GC Biopharma Corp., JCR Pharmaceuticals Co., Ltd., Denali Therapeutics Inc., and RegenxBio Inc., among others.

The Hunter Syndrome Treatment Market is expected to grow at a CAGR of 7.23% from 2026 to 2035.

Increasing awareness and diagnosis of rare genetic disorders, advancements in enzyme replacement therapies, and growing investments in orphan drug development are driving the Hunter Syndrome Treatment Market growth.